http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022265675-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_86b156b60b7ff5b1635ab85d1eeb6590 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 |
| filingDate | 2020-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c3949265ae472aa14db5dc219250275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_389bcf125c29a2028f07eba5531f5715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90cc84c92a2b070a01919aa46f0f2190 |
| publicationDate | 2022-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2022265675-A1 |
| titleOfInvention | Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids |
| abstract | The present invention is directed to the treatment of chemical substance abuse and withdrawal symptoms, especially withdrawal symptoms associated with opioids, utilizing a combination of an effective amount of a cannabinoid, in particular, cannabidiol (CBD) and/or A 9 -tetrahydrocannabinol (THC) in combination with low dosage noribogaine or a derivative salt, solvate or ansolvate thereof to treat withdrawal symptoms, both acute and longer term. It has unexpectedly been discovered that the cannabinoids as described herein work in conjunction with noribogaine to synergistically ameliorate and/or attenuate chemical substance abuse, especially including opioid withdrawal symptoms, both acute and longer term symptoms, such that low dose noribogaine (often in daily dosages of 30 milligrams or less) may be favorably co-administered to a patient suffering from withdrawal symptoms, substantially shortening the QT interval of the patient and providing for a particularly safe and effective method to treat opioid withdrawal symptoms. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023066947-A1 |
| priorityDate | 2019-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID69029446 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID412828005 |
Total number of triples: 23.